|
CLCN3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.62000002091168E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.11360000507344E-08 |
| Normal-vs-Stage2 |
7.402800E-04 |
| Normal-vs-Stage3 |
5.45509970528713E-10 |
| Normal-vs-Stage4 |
7.78830000491837E-09 |
| Stage1-vs-Stage2 |
4.717400E-01 |
| Stage1-vs-Stage3 |
1.020400E-01 |
| Stage1-vs-Stage4 |
8.374100E-02 |
| Stage2-vs-Stage3 |
7.419900E-02 |
| Stage2-vs-Stage4 |
5.326200E-02 |
| Stage3-vs-Stage4 |
6.212400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.66790034508801E-10 |
| Normal-vs-AfricanAmerican |
3.056000E-03 |
| Normal-vs-Asian |
1.00609999997836E-06 |
| Caucasian-vs-AfricanAmerican |
3.089800E-01 |
| Caucasian-vs-Asian |
8.136200E-01 |
| AfricanAmerican-vs-Asian |
2.843000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.92210003469029E-09 |
| Normal-vs-Female |
6.45779996144569E-09 |
| Male-vs-Female |
1.765250E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.49540000002635E-07 |
| Normal-vs-Age(41-60Yrs) |
3.88550003282973E-09 |
| Normal-vs-Age(61-80Yrs) |
1.5893000027134E-08 |
| Normal-vs-Age(81-100Yrs) |
6.844400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.258800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.308000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.350800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.858000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.621800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.984800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.984100E-02 |
| Classical-VS-Follicular |
8.576200E-01 |
| Classical-VS-Other |
1.047390E-01 |
| Classical-VS-Normal |
1.74990000267883E-08 |
| Tall-VS-Follicular |
1.223580E-01 |
| Tall-VS-Other |
3.471200E-01 |
| Tall-VS-Normal |
4.1041000042874E-08 |
| Follicular-VS-Other |
1.854570E-01 |
| Follicular-VS-Normal |
1.81501999999556E-05 |
| Other-VS-Normal |
5.211100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.33360000107186E-08 |
| Normal-vs-N1 |
3.88109999693853E-09 |
| N0-vs-N1 |
4.497800E-02 |
|
|
